BioEP

BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis and prognosis of epilepsy.

Epilepsy is a serious neurological condition that impacts over 65M people around the world.

BioEP is a patented seizure risk score calculated from routine EEG recordings that can enable faster and more accurate diagnosis and prognosis of epilepsy.

Neuronostics is a collaborative organisation and welcomes enquiries from researchers, clinicians and commercial partners.

We are Neuronostics

Neuronostics is a new company (founded 2018) developing a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.

Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.

We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.

LATEST NEWS
Find out the latest news and information from Neuronostics.

Neuronostics win national start up award

9 October 2020 We are delighted to have been awarded the Start Up award from Medilink UK: totally unexpected, and hugely appreciated! It’s a fantastic recognition of all our hard work over... [Read More]

Full stack developer roles

25 September 2020 We’re looking to recruit two full stack developers to join us from January 2021. Across the two roles, one will focus on developing our BioEP platform and the algorithms... [Read More]

Funding secured to develop BioEP technologies

8 September 2020 Today, we can finally share the amazing news that we have been awarded a total of £870,000 of government funding to support two research projects to further develop our... [Read More]